Marie Coutelier1,2,3,4,5,6, Monia B Hammer7, Giovanni Stevanin1,2,3,4,6,8, Marie-Lorraine Monin8, Claire-Sophie Davoine1,2,3,4,6, Fanny Mochel1,2,3,4,8, Pierre Labauge9, Claire Ewenczyk8, Jinhui Ding7, J Raphael Gibbs7, Didier Hannequin10, Judith Melki11,12, Annick Toutain13, Vincent Laugel14,15, Sylvie Forlani1,2,3,4, Perrine Charles8, Emmanuel Broussolle16,17,18, Stéphane Thobois16,17,18, Alexandra Afenjar19, Mathieu Anheim15,20,21, Patrick Calvas22, Giovanni Castelnovo23, Thomas de Broucker24, Marie Vidailhet1,2,3,4,25, Antoine Moulignier26, Robert T Ghnassia27, Chantal Tallaksen1,2,3,4,28, Cyril Mignot29, Cyril Goizet30,31, Isabelle Le Ber1,2,3,4, Elisabeth Ollagnon-Roman32, Jean Pouget33, Alexis Brice1,2,3,4,8, Andrew Singleton7, Alexandra Durr1,2,3,4,8. 1. Institut National de la Santé et de la Recherche Medicale (INSERM) U1127, Paris, France. 2. Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UMR) 7225, Paris, France. 3. Unité Mixte de Recherche en Santé 1127, Université Pierre et Marie Curie (Paris 06), Sorbonne Universités, Paris, France. 4. Institut du Cerveau et de la Moelle Epinière, Paris, France. 5. Laboratory of Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium. 6. Ecole Pratique des Hautes Etudes, Paris Sciences et Lettres Research University, Paris, France. 7. Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland. 8. Centre de Référence de Neurogénétique, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. 9. Service de Neurologie, Hopital Gui de Chauliac, Centre Hospitalier Universitaire (CHU) de Montpellier, Montpellier, France. 10. Service de Génétique, Service de Neurologie, INSERM U1079, Rouen University Hospital, Rouen, France. 11. UMR 1169, INSERM and University Paris Saclay, Le Kremlin Bicêtre, France. 12. Medical Genetics Unit, Centre Hospitalier Sud-Francilien, Corbeil Essonnes, France. 13. Service de Génétique, Centre Hospitalier Universitaire de Tours, INSERM U930, Faculté de Médecine, Université François Rabelais, Tours, France. 14. Service de Pédiatrie 1, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 15. Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France. 16. Service de Neurologie C, Hôpital Neurologique Pierre-Wertheimer, Hospices Civils de Lyon, Bron, France. 17. Centre de Neurosciences Cognitives, Centre National de la Recherche Scientifique (CNRS)-UMR 5229, Bron, France. 18. Université de Lyon, Université Claude-Bernard-Lyon I, Villeurbanne, France. 19. Service de Génétique et Centre de Référence Pour les Malformations et les Maladies Congénitales du Cervelet, AP-HP, Paris, France. 20. Département de Neurologie, Hôpital de Hautepierre, CHU de Strasbourg, Strasbourg, France. 21. Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM U964, CNRS-UMR 7104, Université de Strasbourg, Illkirch, France. 22. Service de Génétique Médicale, CHU de Toulouse, Hôpital Purpan, Toulouse, France. 23. Service de Neurologie, CHU Caremeau, Nîmes, France. 24. Service de Neurologie, Centre Hospitalier de Saint-Denis, Saint-Denis, France. 25. Département des Maladies du Système Nerveux, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France. 26. Service de Neurologie, Fondation Ophtalmologique A. de Rothschild, Paris, France. 27. private practice, Chelles, France. 28. currently affiliated with Department of Neurology, Oslo University Hospital; and Faculty of Medicine, Oslo University, Oslo, Norway. 29. Département de Génétique and Centre de Référence Déficiences Intellectuelles de Causes Rares, Groupe Hospitalier Pitié Salpêtrière, AP-HP, Paris, France. 30. Laboratoire Maladies Rares, Génétique et Métabolisme, Université de Bordeaux, Bordeaux, France. 31. Service de Génétique Médicale, CHU Pellegrin, Bordeaux, France. 32. Service de Neurogénétique, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. 33. Centre de Référence des Maladies Neuromusculaires et de la Sclérose Latérale Amyotrophique, Assistance Publique-Hôpitaux de Marseille, Aix Marseille Université, Hôpital de La Timone, Marseille, France.
Abstract
Importance: Molecular diagnosis is difficult to achieve in disease groups with a highly heterogeneous genetic background, such as cerebellar ataxia (CA). In many patients, candidate gene sequencing or focused resequencing arrays do not allow investigators to reach a genetic conclusion. Objectives: To assess the efficacy of exome-targeted capture sequencing to detect mutations in genes broadly linked to CA in a large cohort of undiagnosed patients and to investigate their prevalence. Design, Setting, and Participants: Three hundred nineteen index patients with CA and without a history of dominant transmission were included in the this cohort study by the Spastic Paraplegia and Ataxia Network. Centralized storage was in the DNA and cell bank of the Brain and Spine Institute, Salpetriere Hospital, Paris, France. Patients were classified into 6 clinical groups, with the largest being those with spastic ataxia (ie, CA with pyramidal signs [n = 100]). Sequencing was performed from January 1, 2014, through December 31, 2016. Detected variants were classified as very probably or definitely causative, possibly causative, or of unknown significance based on genetic evidence and genotype-phenotype considerations. Main Outcomes and Measures: Identification of variants in genes broadly linked to CA, classified in pathogenicity groups. Results: The 319 included patients had equal sex distribution (160 female [50.2%] and 159 male patients [49.8%]; mean [SD] age at onset, 27.9 [18.6] years). The age at onset was younger than 25 years for 131 of 298 patients (44.0%) with complete clinical information. Consanguinity was present in 101 of 298 (33.9%). Very probable or definite diagnoses were achieved for 72 patients (22.6%), with an additional 19 (6.0%) harboring possibly pathogenic variants. The most frequently mutated genes were SPG7 (n = 14), SACS (n = 8), SETX (n = 7), SYNE1 (n = 6), and CACNA1A (n = 6). The highest diagnostic rate was obtained for patients with an autosomal recessive CA with oculomotor apraxia-like phenotype (6 of 17 [35.3%]) or spastic ataxia (35 of 100 [35.0%]) and patients with onset before 25 years of age (41 of 131 [31.3%]). Peculiar phenotypes were reported for patients carrying KCND3 or ERCC5 variants. Conclusions and Relevance: Exome capture followed by targeted analysis allows the molecular diagnosis in patients with highly heterogeneous mendelian disorders, such as CA, without prior assumption of the inheritance mode or causative gene. Being commonly available without specific design need, this procedure allows testing of a broader range of genes, consequently describing less classic phenotype-genotype correlations, and post hoc reanalysis of data as new genes are implicated in the disease.
Importance: Molecular diagnosis is difficult to achieve in disease groups with a highly heterogeneous genetic background, such as cerebellar ataxia (CA). In many patients, candidate gene sequencing or focused resequencing arrays do not allow investigators to reach a genetic conclusion. Objectives: To assess the efficacy of exome-targeted capture sequencing to detect mutations in genes broadly linked to CA in a large cohort of undiagnosed patients and to investigate their prevalence. Design, Setting, and Participants: Three hundred nineteen index patients with CA and without a history of dominant transmission were included in the this cohort study by the Spastic Paraplegia and Ataxia Network. Centralized storage was in the DNA and cell bank of the Brain and Spine Institute, Salpetriere Hospital, Paris, France. Patients were classified into 6 clinical groups, with the largest being those with spastic ataxia (ie, CA with pyramidal signs [n = 100]). Sequencing was performed from January 1, 2014, through December 31, 2016. Detected variants were classified as very probably or definitely causative, possibly causative, or of unknown significance based on genetic evidence and genotype-phenotype considerations. Main Outcomes and Measures: Identification of variants in genes broadly linked to CA, classified in pathogenicity groups. Results: The 319 included patients had equal sex distribution (160 female [50.2%] and 159 male patients [49.8%]; mean [SD] age at onset, 27.9 [18.6] years). The age at onset was younger than 25 years for 131 of 298 patients (44.0%) with complete clinical information. Consanguinity was present in 101 of 298 (33.9%). Very probable or definite diagnoses were achieved for 72 patients (22.6%), with an additional 19 (6.0%) harboring possibly pathogenic variants. The most frequently mutated genes were SPG7 (n = 14), SACS (n = 8), SETX (n = 7), SYNE1 (n = 6), and CACNA1A (n = 6). The highest diagnostic rate was obtained for patients with an autosomal recessive CA with oculomotor apraxia-like phenotype (6 of 17 [35.3%]) or spastic ataxia (35 of 100 [35.0%]) and patients with onset before 25 years of age (41 of 131 [31.3%]). Peculiar phenotypes were reported for patients carrying KCND3 or ERCC5 variants. Conclusions and Relevance: Exome capture followed by targeted analysis allows the molecular diagnosis in patients with highly heterogeneous mendelian disorders, such as CA, without prior assumption of the inheritance mode or causative gene. Being commonly available without specific design need, this procedure allows testing of a broader range of genes, consequently describing less classic phenotype-genotype correlations, and post hoc reanalysis of data as new genes are implicated in the disease.
Authors: V Campuzano; L Montermini; Y Lutz; L Cova; C Hindelang; S Jiralerspong; Y Trottier; S J Kish; B Faucheux; P Trouillas; F J Authier; A Dürr; J L Mandel; A Vescovi; M Pandolfo; M Koenig Journal: Hum Mol Genet Date: 1997-10 Impact factor: 6.150
Authors: Geraldine A Van der Auwera; Mauricio O Carneiro; Christopher Hartl; Ryan Poplin; Guillermo Del Angel; Ami Levy-Moonshine; Tadeusz Jordan; Khalid Shakir; David Roazen; Joel Thibault; Eric Banks; Kiran V Garimella; David Altshuler; Stacey Gabriel; Mark A DePristo Journal: Curr Protoc Bioinformatics Date: 2013
Authors: Brent L Fogel; Hane Lee; Joshua L Deignan; Samuel P Strom; Sibel Kantarci; Xizhe Wang; Fabiola Quintero-Rivera; Eric Vilain; Wayne W Grody; Susan Perlman; Daniel H Geschwind; Stanley F Nelson Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302
Authors: K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh Journal: Science Date: 1995-06-23 Impact factor: 47.728
Authors: Pablo Cingolani; Viral M Patel; Melissa Coon; Tung Nguyen; Susan J Land; Douglas M Ruden; Xiangyi Lu Journal: Front Genet Date: 2012-03-15 Impact factor: 4.599
Authors: Jenny C Taylor; Hilary C Martin; Stefano Lise; John Broxholme; Jean-Baptiste Cazier; Andy Rimmer; Alexander Kanapin; Gerton Lunter; Simon Fiddy; Chris Allan; A Radu Aricescu; Moustafa Attar; Christian Babbs; Jennifer Becq; David Beeson; Celeste Bento; Patricia Bignell; Edward Blair; Veronica J Buckle; Katherine Bull; Ondrej Cais; Holger Cario; Helen Chapel; Richard R Copley; Richard Cornall; Jude Craft; Karin Dahan; Emma E Davenport; Calliope Dendrou; Olivier Devuyst; Aimée L Fenwick; Jonathan Flint; Lars Fugger; Rodney D Gilbert; Anne Goriely; Angie Green; Ingo H Greger; Russell Grocock; Anja V Gruszczyk; Robert Hastings; Edouard Hatton; Doug Higgs; Adrian Hill; Chris Holmes; Malcolm Howard; Linda Hughes; Peter Humburg; David Johnson; Fredrik Karpe; Zoya Kingsbury; Usha Kini; Julian C Knight; Jonathan Krohn; Sarah Lamble; Craig Langman; Lorne Lonie; Joshua Luck; Davis McCarthy; Simon J McGowan; Mary Frances McMullin; Kerry A Miller; Lisa Murray; Andrea H Németh; M Andrew Nesbit; David Nutt; Elizabeth Ormondroyd; Annette Bang Oturai; Alistair Pagnamenta; Smita Y Patel; Melanie Percy; Nayia Petousi; Paolo Piazza; Sian E Piret; Guadalupe Polanco-Echeverry; Niko Popitsch; Fiona Powrie; Chris Pugh; Lynn Quek; Peter A Robbins; Kathryn Robson; Alexandra Russo; Natasha Sahgal; Pauline A van Schouwenburg; Anna Schuh; Earl Silverman; Alison Simmons; Per Soelberg Sørensen; Elizabeth Sweeney; John Taylor; Rajesh V Thakker; Ian Tomlinson; Amy Trebes; Stephen Rf Twigg; Holm H Uhlig; Paresh Vyas; Tim Vyse; Steven A Wall; Hugh Watkins; Michael P Whyte; Lorna Witty; Ben Wright; Chris Yau; David Buck; Sean Humphray; Peter J Ratcliffe; John I Bell; Andrew Om Wilkie; David Bentley; Peter Donnelly; Gilean McVean Journal: Nat Genet Date: 2015-05-18 Impact factor: 38.330
Authors: Andrea H Németh; Alexandra C Kwasniewska; Stefano Lise; Ricardo Parolin Schnekenberg; Esther B E Becker; Katarzyna D Bera; Morag E Shanks; Lorna Gregory; David Buck; M Zameel Cader; Kevin Talbot; Rajith de Silva; Nicholas Fletcher; Rob Hastings; Sandeep Jayawant; Patrick J Morrison; Paul Worth; Malcolm Taylor; John Tolmie; Mary O'Regan; Ruth Valentine; Emily Packham; Julie Evans; Anneke Seller; Jiannis Ragoussis Journal: Brain Date: 2013-09-11 Impact factor: 13.501
Authors: Laurence Gauquelin; Taila Hartley; Mark Tarnopolsky; David A Dyment; Bernard Brais; Michael T Geraghty; Martine Tétreault; Sohnee Ahmed; Samantha Rojas; Karine Choquet; Jacek Majewski; François Bernier; Allan Micheil Innes; Guy Rouleau; Oksana Suchowersky; Kym M Boycott; Grace Yoon Journal: Mov Disord Clin Pract Date: 2020-09-29
Authors: Shijing Wu; Zixi Sun; Tian Zhu; Richard G Weleber; Paul Yang; Xing Wei; Mark E Pennesi; Ruifang Sui Journal: Exp Eye Res Date: 2020-10-22 Impact factor: 3.467
Authors: Andreas Traschütz; Selina Reich; Astrid D Adarmes; Mathieu Anheim; Mahmoud Reza Ashrafi; Jonathan Baets; A Nazli Basak; Enrico Bertini; Bernard Brais; Cynthia Gagnon; Janina Gburek-Augustat; Hasmet A Hanagasi; Anna Heinzmann; Rita Horvath; Peter de Jonghe; Christoph Kamm; Peter Klivenyi; Thomas Klopstock; Martina Minnerop; Alexander Münchau; Mathilde Renaud; Richard H Roxburgh; Filippo M Santorelli; Tommaso Schirinzi; Deborah A Sival; Dagmar Timmann; Stefan Vielhaber; Michael Wallner; Bart P van de Warrenburg; Ginevra Zanni; Stephan Zuchner; Thomas Klockgether; Rebecca Schüle; Ludger Schöls; Matthis Synofzik Journal: Front Neurol Date: 2021-06-25 Impact factor: 4.003